Literature DB >> 15372536

Porphyric neuropathy.

James W Albers1, John K Fink.   

Abstract

The hepatic porphyrias are a group of rare metabolic disorders characterized by enzymatic defects in the biosynthesis of heme, a metalloporphyrin that is the principal product of porphyrin metabolism. The hepatic porphyrias are genetically transmitted as autosomal-dominant disorders with variable expression that produce a particularly severe form of neuropathy. Most medical students readily recognize acute attacks of porphyria when the classic triad of abdominal pain, psychosis, and neuropathy is present. Yet, porphyric neuropathy is a source of confusion in practice, and patients with porphyria rarely receive the correct diagnosis early in the course of the illness. Porphyric neuropathy is manifest by symptoms, signs, and cerebrospinal fluid abnormalities resembling acute Guillain-Barré syndrome. However, accompanying psychological features, a proximal predilection of asymmetric weakness, and electrodiagnostic findings indicative of an axonal polyradiculopathy or neuronopathy all suggest the diagnosis of porphyria. Confirmation of the diagnosis depends on use of appropriate laboratory studies. The underlying pathophysiology of porphyric neuropathy has not been established, but it may be related to direct neurotoxicity of elevated levels of delta-aminolevulinic acid. The severity of the neuropathy and the availability of potential treatments, including avoidance of provocative factors, make identification important.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15372536     DOI: 10.1002/mus.20137

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  25 in total

1.  Suxamethonium in the intensive care unit: "Fool me once, shame on you; fool me twice, shame on me".

Authors:  Hannah Church; Sue Sinclair; Tessa Oelofse
Journal:  Intensive Care Med       Date:  2007-10-18       Impact factor: 17.440

2.  High selectivity of the γ-aminobutyric acid transporter 2 (GAT-2, SLC6A13) revealed by structure-based approach.

Authors:  Avner Schlessinger; Matthias B Wittwer; Amber Dahlin; Natalia Khuri; Massimiliano Bonomi; Hao Fan; Kathleen M Giacomini; Andrej Sali
Journal:  J Biol Chem       Date:  2012-08-29       Impact factor: 5.157

Review 3.  Acute hepatic porphyrias: Recommendations for evaluation and long-term management.

Authors:  Manisha Balwani; Bruce Wang; Karl E Anderson; Joseph R Bloomer; D Montgomery Bissell; Herbert L Bonkovsky; John D Phillips; Robert J Desnick
Journal:  Hepatology       Date:  2017-09-04       Impact factor: 17.425

Review 4.  The acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 5.  Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity.

Authors:  Mohamed A Kamal; Richard F Keep; David E Smith
Journal:  Drug Metab Pharmacokinet       Date:  2008       Impact factor: 3.614

Review 6.  Porphyric Neuropathy: Pathophysiology, Diagnosis, and Updated Management.

Authors:  Mohamed Kazamel; Robert J Desnick; John G Quigley
Journal:  Curr Neurol Neurosci Rep       Date:  2020-10-07       Impact factor: 5.081

7.  Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease.

Authors:  Barney E Dwyer; Mark A Smith; Sandy L Richardson; George Perry; Xiongwei Zhu
Journal:  Neurosci Lett       Date:  2009-05-27       Impact factor: 3.046

8.  Acute intermittent porphyria: A case report

Authors:  José Bustos; Ledmar Vargas; Ricardo Quintero
Journal:  Biomedica       Date:  2020-03-01       Impact factor: 0.935

Review 9.  Molecular modeling and ligand docking for solute carrier (SLC) transporters.

Authors:  Avner Schlessinger; Natalia Khuri; Kathleen M Giacomini; Andrej Sali
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

10.  A Case of Acute Intermittent Porphyria Mimicking Guillain-Barré Syndrome.

Authors:  Belgin Mutluay; Ayhan Köksal; Rabia Gökçen Gözübatik Çelık; Hafsa Hicret Bülbül
Journal:  Noro Psikiyatr Ars       Date:  2019-10-15       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.